Study to Evaluate Pharmacokinetics of Dipyridamole in Three New Formulations of Asasantin ER in Healthy Female and Male Subjects

NCT02273544 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Asasantin ER (new formulation - low)
DRUG: Asasantin ER (new formulation - medium)
DRUG: Asasantin ER (new formulation - high)
DRUG: Asasantin ER - commercial formulation

Sponsor

Boehringer Ingelheim